These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1123 related articles for article (PubMed ID: 11441305)

  • 1. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
    Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
    Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants.
    Stratmann A; Acker T; Burger AM; Amann K; Risau W; Plate KH
    Int J Cancer; 2001 Feb; 91(3):273-82. PubMed ID: 11169947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.
    Taylor AP; Osorio L; Craig R; Raleigh JA; Ying Z; Goldenberg DM; Blumenthal RD
    Clin Cancer Res; 2002 Apr; 8(4):1213-22. PubMed ID: 11948135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenic treatment strategies for malignant brain tumors.
    Kirsch M; Schackert G; Black PM
    J Neurooncol; 2000; 50(1-2):149-63. PubMed ID: 11245274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
    Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
    Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
    Bunone G; Vigneri P; Mariani L; Butó S; Collini P; Pilotti S; Pierotti MA; Bongarzone I
    Am J Pathol; 1999 Dec; 155(6):1967-76. PubMed ID: 10595926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic therapy targeting factors that enhance endothelial cell survival.
    Liu W; Reinmuth N; Stoeltzing O; Parikh AA; Fan F; Ahmad SA; Jung YD; Ellis LM
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):96-103. PubMed ID: 12138403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain.
    Péoch M; Farion R; Hiou A; Le Bas JF; Pasquier B; Rémy C
    Anticancer Res; 2002; 22(4):2147-51. PubMed ID: 12174896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiopoietin inhibitors: A review on targeting tumor angiogenesis.
    Parmar D; Apte M
    Eur J Pharmacol; 2021 May; 899():174021. PubMed ID: 33741382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
    Drevs J; Müller-Driver R; Wittig C; Fuxius S; Esser N; Hugenschmidt H; Konerding MA; Allegrini PR; Wood J; Hennig J; Unger C; Marmé D
    Cancer Res; 2002 Jul; 62(14):4015-22. PubMed ID: 12124335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.
    Vajkoczy P; Farhadi M; Gaumann A; Heidenreich R; Erber R; Wunder A; Tonn JC; Menger MD; Breier G
    J Clin Invest; 2002 Mar; 109(6):777-85. PubMed ID: 11901186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF receptor signaling in tumor angiogenesis.
    McMahon G
    Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tie-1: A potential target for anti-angiogenesis therapy.
    Yang P; Chen N; Jia JH; Gao XJ; Li SH; Cai J; Wang Z
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):615-622. PubMed ID: 26489611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial survival factors as targets for antineoplastic therapy.
    Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
    Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.